Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure

The New England Journal of Medicine
C W YancyU.S. Carvedilol Heart Failure Study Group

Abstract

The benefits of angiotensin-converting-enzyme inhibitors and beta-blockers may be smaller in black patients than in patients of other races, but it is unknown whether race influences the response to carvedilol in patients with chronic heart failure. In the U.S. Carvedilol Heart Failure Trials Program, 217 black and 877 nonblack patients (in New York Heart Association class II, III, or IV and with a left ventricular ejection fraction of no more than 0.35) were randomly assigned to receive placebo or carvedilol (at doses of 6.25 to 50 mg twice daily) for up to 15 months. The effects of carvedilol on ejection fraction, clinical status, and major clinical events were retrospectively compared between black and nonblack patients. As compared with placebo, carvedilol lowered the risk of death from any cause or hospitalization for any reason by 48 percent in black patients and by 30 percent in nonblack patients. Carvedilol reduced the risk of worsening heart failure (heart failure leading to death, hospitalization, or a sustained increase in medication) by 54 percent in black patients and by 51 percent in nonblack patients. The ratios of the relative risks associated with carvedilol for these two outcome variables in black as compared ...Continue Reading

References

Jun 8, 1979·Science·A W VoorsS E Shuler
Jan 1, 1978·Annals of Internal Medicine·S B LevyR A Stone
Jan 1, 1992·Journal of Hypertension·J H PrattD P Henry
Mar 12, 1990·The American Journal of Medicine·L J Haywood
Oct 24, 1986·JAMA : the Journal of the American Medical Association·L X CubedduT Eades
May 1, 1983·Annals of Internal Medicine·F C LuftJ Z Miller
Oct 4, 1995·JAMA : the Journal of the American Medical Association·M AlexanderE Washington
Jan 1, 1995·Hypertension·P J MillsR A Nelesen
Apr 16, 1994·BMJ : British Medical Journal·J MayetS A McG Thom
Dec 1, 1995·American Journal of Hypertension·E Saunders
Aug 26, 1998·Progress in Cardiovascular Diseases·G FeuersteinR R Ruffolo
Feb 25, 1999·The New England Journal of Medicine·D L DriesM J Domanski
Mar 13, 1999·Archives of Internal Medicine·J HeP K Whelton
Jan 8, 2000·Clinical Cardiology·A AfzalS M Jafri
Mar 16, 2001·The American Journal of Cardiology·J M FoodyM S Lauer

❮ Previous
Next ❯

Citations

Jun 24, 2004·JAMA : the Journal of the American Medical Association·Pamela SankarPaul Spicer
Jan 5, 2002·Clinical Cardiology·W L Lombardi, E M Gilbert
Jul 23, 2005·Current Heart Failure Reports·Thomas W Wallace, Mark H Drazner
Jul 23, 2005·Current Heart Failure Reports·Jalal K Ghali
May 25, 2007·Current Heart Failure Reports·S D Naik, Ronald S Freudenberger
Aug 3, 2005·Current Hypertension Reports·Shawna D Nesbitt
Jul 16, 2008·Current Hypertension Reports·Clyde W Yancy
Oct 25, 2003·Current Treatment Options in Cardiovascular Medicine·Wendy M. Book, Brenda J. Hott
Jul 12, 2005·Current Treatment Options in Cardiovascular Medicine·Sandeep A Kamath, Clyde W Yancy
Jan 1, 2003·Comprehensive Therapy·Ravi K GargAllen S Anderson
Dec 12, 2003·The Annals of Thoracic Surgery·Arthur M Feldman
Aug 2, 2003·American Heart Journal·Stephanie H DunlapKirkwood F Adams
Jun 14, 2003·Current Problems in Cardiology·George A MensahWayne H Giles
Apr 8, 2003·Journal of the American College of Cardiology·Ori Ben-Yehuda
Nov 7, 2003·Critical Care Clinics·Germán R Núñez
Jun 30, 2009·Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology·Haig TcheurekdjianEsteban González Burchard
May 3, 2001·The New England Journal of Medicine·R S Schwartz
May 5, 2001·The New England Journal of Medicine·A J Wood
Jun 2, 2001·The New England Journal of Medicine·E Braunwald
Sep 8, 2001·The New England Journal of Medicine·H L McLeod
Mar 11, 2005·The New England Journal of Medicine·Andrew E Moran, Richard S Cooper
Nov 10, 2004·The New England Journal of Medicine·Anne L TaylorUNKNOWN African-American Heart Failure Trial Investigators
Jan 5, 2002·The New England Journal of Medicine·B J McNeil
Feb 17, 2005·Dimensions of Critical Care Nursing : DCCN·Leslie C Hussey, Sonya Hardin
Feb 27, 2007·JAAPA : Official Journal of the American Academy of Physician Assistants·Natalie Schmitz
Jan 31, 2003·The Journal of Clinical Hypertension·Jackson T Wright, Janice Douglas
Oct 7, 2003·Annual Review of Genomics and Human Genetics·Rick A Kittles, Kenneth M Weiss
Jan 4, 2007·The Journal of Clinical Investigation·Brent R DeGeorge, Walter J Koch
Oct 19, 2007·Medical Care Research and Review : MCRR·Andrew M DavisElbert S Huang
May 26, 2009·BMC Medical Genomics·Edward Ramos, Charles Rotimi
Jul 30, 2009·Circulation Journal : Official Journal of the Japanese Circulation Society·Masanori Asakura, Masafumi Kitakaze
Nov 29, 2007·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Jalal K GhaliUNKNOWN A-HeFT Investigators
Dec 16, 2003·American Journal of Pharmacogenomics : Genomics-related Research in Drug Development and Clinical Practice·Sandra Soo-Jin Lee
Oct 5, 2010·Drugs & Aging·Roberto AntonicelliGianfranco Parati
Jun 2, 2011·Future Cardiology·Nicholas B Norgard, Gina M Prescott
May 10, 2011·Medicinski pregled·Vesna V Radović

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.